Increasing Prevalence of Infectious Diseases and Emergence of Covid-19 to Augment Growth of Vaccine Adjuvant Market
In immunology, an
adjuvant is any material that enhances and/or decreases the immune response to
a vaccine or other agent. The word "adjuvant" derives from the Latin
phrase adiuvare, which means to assist or help. The usual definition of an adjuvant
in this context is a substance added to enhance the effectiveness of a
biological agent or product in the process of eliciting an immune response.
Market
Dynamics
Increasing prevalence
of infectious diseases is expected to propel growth of the global vaccine adjuvant
market. For instance, in May 2019,
according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg)
positivity and its associated factors in Rwanda’, published in May 2019, in BMC
Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in
the study population.
Moreover, increasing
adoption of adjuvant technologies is also expected to aid in growth of the
market. For instance, in January 2021, Oragenics, a developer of antibiotics
against infectious diseases and treatments for oral mucositis, entered into a
material transfer agreement with Adjuvance Technologies for use of the adjuvant
TQL1055 in Oragenics’ Terra CoV-2 vaccine against COVID-19. Similarly, in October 2020, Medigen
Vaccine Biologics Corporation, a biopharmaceutical company, and Dynavax
Technologies Corporation, a biopharmaceutical company focused on R&D in novel
vaccines, announced that Medigen Vaccine Biologics Corporation has obtained a
Taiwan government subsidy for successfully initiating a Phase 1 clinical trial
in Taiwan for its COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant.
Emergence
of Covid-19 is expected to offer lucrative growth opportunities for players in
the
global vaccine
adjuvant market. For instance, globally, as of 9:55am
CET, 4 March 2021, there have been 114,653,749 confirmed cases of COVID-19,
including 2,550,500 deaths, reported to the World Health Organization.
Moreover, R&D in novel vaccine dose sparing adjuvant is also expected to
aid in growth of the market. For instance, in January 2021, Mountain Valley MD
Holdings Inc., a biotech and life sciences company, filed a POROUS ALUMINUM
NANO-STRUCTURED ADJUVANT patent to protect the company's work on vaccine dose
sparing.
Competitive
Analysis
Major players operating
in the global vaccine adjuvant market include, SEPPIC Inc., Novavax, Inc.,
Hayashibara Co., Ltd., SPI Pharma Inc., Invivogen, Avanti Polar Lipids, Inc.,
MPV Technologies, OZ Biosciences, GlaxoSmithKline, Agenus, Inc., Brenntag Biosector,
Spectrum Pharmaceuticals. Inc., Sigma Aldrich, Adjuatis, Vaxliant, Adjuvance
Technologies, Inc., GlaxoSmithKline plc., Puma Biotechnology, Tj Kaiwei,
Zhouyue, Aphios, and CSL Limited.
Major players operating
in the global vaccine adjuvant market are focused on adopting various
strategies to enhance their market share. For instance, in May 2020,
GlaxoSmithKline announced plans to produce one billion doses in 2021 of its
vaccine adjuvant system to support numerous COVID-19 vaccine candidates.

Comments
Post a Comment